U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06799637) titled 'Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments' on Dec. 25, 2024.
Brief Summary: This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies or are intolerant to such therapies. The study consists of two parts: a dose escalation part and a dose expansion part.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: XNW28012
Eligible subjects will receive XNW28012 every 3 weeks (Q3W) until intolerant toxicity, ...